Cargando…

REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis

BACKGROUND: In a placebo‐controlled, randomized phase 2 trial (ClinicalTrials.gov identifier NCT01900743), regorafenib improved progression‐free survival (PFS) for patients with doxorubicin‐pretreated advanced nonadipocytic sarcoma. A quality‐adjusted time without symptoms of progression or toxicity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berry, Vincent, Basson, Laurent, Bogart, Emilie, Mir, Olivier, Blay, Jean‐Yves, Italiano, Antoine, Bertucci, François, Chevreau, Christine, Clisant‐Delaine, Stéphanie, Liegl‐Antzager, Bernadette, Tresch‐Bruneel, Emmanuelle, Wallet, Jennifer, Taieb, Sophie, Decoupigny, Emilie, Le Cesne, Axel, Brodowicz, Thomas, Penel, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485075/ https://www.ncbi.nlm.nih.gov/pubmed/28295221 http://dx.doi.org/10.1002/cncr.30661

Ejemplares similares

Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study
por: Brodowicz, Thomas, et al.
Publicado: (2020)

Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial
por: Brodowicz, Thomas, et al.
Publicado: (2015)

Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO)
por: Lebellec, Loic, et al.
Publicado: (2016)

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)(†)
por: Bompas, E., et al.
Publicado: (2015)

Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial
por: Pannier, Diane, et al.
Publicado: (2018)

Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study
por: Le Cesne, A., et al.
Publicado: (2023)

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
por: Adenis, A, et al.
Publicado: (2013)

Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
por: Lebellec, Loïc, et al.
Publicado: (2018)

Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: a randomised phase III trial
por: Hutt, Emilie, et al.
Publicado: (2018)

CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
por: Boudin, Laurys, et al.
Publicado: (2022)

PARP1 expression in soft tissue sarcomas is a poor‐prognosis factor and a new potential therapeutic target
por: Bertucci, François, et al.
Publicado: (2019)

Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas
por: Brahmi, M., et al.
Publicado: (2021)

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma
por: Maillard, Maud, et al.
Publicado: (2020)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010)

Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
por: Bertucci, Francois, et al.
Publicado: (2022)

Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor
por: Grellety, Thomas, et al.
Publicado: (2015)

A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome
por: Rochefort, Pauline, et al.
Publicado: (2017)

Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)
por: Moreau-Bachelard, C., et al.
Publicado: (2022)

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program
por: Adenis, Antoine, et al.
Publicado: (2016)

Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis
por: Debaudringhien, M., et al.
Publicado: (2022)

Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program
por: Adenis, Antoine, et al.
Publicado: (2016)

Predictive Value of Clinical Judgment of Tumour Progression in Phase II Trials
por: Kotecki, Nuria, et al.
Publicado: (2012)

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group
por: Khalifa, J., et al.
Publicado: (2015)

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
por: Blay, Jean-Yves, et al.
Publicado: (2013)

A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery
por: Pautier, P., et al.
Publicado: (2021)

Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study
por: Bompas, Emmanuelle, et al.
Publicado: (2018)

Midazolam sedation in palliative medicine: retrospective study in a French center for cancer control
por: Gamblin, Vincent, et al.
Publicado: (2020)

ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based case–control study—study protocol
por: Lacourt, Aude, et al.
Publicado: (2019)

The off-label use of targeted therapies in sarcomas: the OUTC’S program
por: Eberst, Lauriane, et al.
Publicado: (2014)

Frequency of Certain Established Risk Factors in Soft Tissue Sarcomas in Adults: A Prospective Descriptive Study of 658 Cases
por: Penel, Nicolas, et al.
Publicado: (2008)

A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
por: Cassier, P A, et al.
Publicado: (2013)

Erythema multiforme induced by regorafenib
por: Matsunaga, Mototsugu, et al.
Publicado: (2017)

Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma
por: Dufresne, A., et al.
Publicado: (2020)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
por: Fu, Qiang, et al.
Publicado: (2019)

Incidence and risk of regorafenib-induced hepatotoxicity
por: Zhao, Bin, et al.
Publicado: (2017)

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Characterization of Glioblastoma Cells Response to Regorafenib
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2022)

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer
por: Adenis, Antoine, et al.
Publicado: (2021)

Tumor Calcification: A New Response Pattern of Myxoid Liposarcoma to Trabectedin
por: Turpin, Anthony, et al.
Publicado: (2014)

Improvement of the initial management of sarcomas after the dissemination of evidence-based guidelines depends on the primary sarcoma location: a population-based study
por: Ligier, Karine, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8blo88kfc1f3j2gto4namj022e